Dr. Vaughn is actively involved in both clinical and translational research for patient with IBD. The intestinal microbiota has recently been identified as a critical component of many intestinal pathways including immune tolerance and inflammation. Dr. Vaughn is working in collaboration with Dr. Alexander Khoruts to continue to understand how the microbiota functions to induce inflammation or tolerance. Additionally, Dr. Vaughn has been a strong proponent for therapeutic drug monitoring. This includes monitoring drug levels for patient on anti-TNFs such as infliximab and adalimumab. His research demonstrates that by close monitoring of these medication and titration to a therapeutic window, patients have more effective disease control and less chance of developing anti-drug antibodies.He continues to study the effect of therapeutic drug monitoring on antibody development.